IL-37 Is a Novel Proangiogenic Factor of Developmental and Pathological Angiogenesis
Tianshu Yang,* Qing Lin,* Mengmeng Zhao,* Yongguang Hu,* Ying Yu, Jiayi Jin, Hongyan Zhou, Xiao Hu, Rongbin Wei, Xuetao Zhang, Xiaoping Yang, Gaoqin Liu, Peirong Lu, Guotong Xu, Jianhua Yang, David B. Corry, Shao Bo Su, Shangfeng Liu, Xialin Liu pathologies. For example, IL-37 is detected in tumor cells of breast carcinoma and infiltrating plasma cells in colon carcinoma. 18 Moreover, IL-37 is upregulated in the synovial tissue from patients with rheumatoid arthritis. 10 However, to the best of our knowledge, no studies have linked IL-37 to the function of ECs.
In this study, we have found that IL-37 is a novel and potent proangiogenic cytokine in developmental and pathological angiogenesis. We provide evidence that IL-37 enhanced EC proliferation, migration, and capillary formation in vitro and promoted vessel sprouting from aortic rings ex vivo with potency comparable with that of VEGF. Matrigel plugs incorporated with increasing dose of IL-37 displayed increased angiogenesis in a dose-dependent manner. Furthermore, we have used models of developmental and pathological angiogenesis to show that IL-37 promoted neovascularization in mouse model of retinal vascularization and oxygen-induced retinopathy (OIR). These results unveiled IL-37 as a novel regulator of pathophysiological angiogenesis.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

IL-37 Expression Is Upregulated by Hypoxia in ECs
Currently, no studies to our knowledge have demonstrated endothelial expression of IL-37. We thus determined the expression of IL-37 in ECs and found that IL-37 protein expression were detected in both large and small vascular ECs, including human umbilical vein endothelial cells (HUVECs) and human microvascular endothelial cells (HMEC-1; Figure IA in the online-only Data Supplement). As hypoxia is an important pathophysiological condition for the induction of angiogenesis, to determine whether IL-37 expression is regulated by hypoxia, HUVECs were cultivated in hypoxic environment (0.1% O 2 ) for 24 hours. The expression of IL-37 was induced by hypoxia as determined by real-time polymerase chain reaction ( Figure IB in the onlineonly Data Supplement). Because IL-37 is produced as a precursor that needs to be processed to release its mature form, we analyzed both pro-and mature form of IL-37 in HUVECs under hypoxic conditions. Both pro-and mature form of IL-37 were markedly induced by hypoxia in HUVECs ( Figure 1A ), suggesting that hypoxia induced expression and maturation of IL-37. We thus further determined whether IL-37 secretion can be induced by hypoxia. As shown in Figure 1B , hypoxia stimulated IL-37 secretion in the supernatant of HUVECs as determined by ELISA.
Moreover, to understand the mechanism underlying the upregulation of IL-37 during hypoxia, we have knocked down hypoxia-inducible factor 1α (HIF-1α), the principle transcriptional activator that orchestrates hypoxia response, and examined the expression levels of IL-37. The result showed that knockdown of HIF-1α expression inhibited hypoxia-induced upregulation of IL-37 mRNA and protein levels, indicating that IL-37 expression was regulated by proangiogenic hypoxic signaling ( Figure II in the online-only Data Supplement). Consistently, we observed that IL-37 expression in HUVECs was upregulated by hypoxia as determined by immunostaining, which showed that IL-37 was localized to both cytoplasm and nucleus in HUVECs ( Figure 1C) . However, the expression of IL-37 in HUVECs was not affected by the principle angiogenic growth factor VEGF ( Figure IC in the online-only Data Supplement). These results together established that IL-37 is expressed in human ECs and upregulated by proangiogenic hypoxic signaling.
IL-37 Promotes EC Proliferation, Tube Formation, and Ex Vivo Sprouting of Aortae
To address the role of IL-37 in angiogenesis, we used in vitro models of cell proliferation and tube formation in cultured human ECs. We found that supplementation of recombinant IL-37 in cell culture medium significantly stimulated HUVEC proliferation at concentrations ranging from 0.01 to 10 ng/mL in a dose-dependent manner, with potency comparable with that of VEGF (Figure 2A ). IL-37 also stimulated HMEC-1 cell proliferation when used at 0.03 to 3 ng/mL ( Figure III in the online-only Data Supplement). The biologically optimal concentration of IL-37 for EC proliferation is ≈1 ng/mL. Similar to its effect on proliferation, IL-37 significantly promoted the formation of capillary-like structures on Matrigel, as quantified by total tubule length and branching points ( Figure 2C and 2D) . To verify the specificity of recombinant IL-37, the effect of IL-37 on EC proliferation were validated by blockade of IL-37 with IL-37-neutralizing antibodies from different suppliers ( Figure  IV in the online-only Data Supplement). We next characterized IL-37's proangiogenic effect by assessing the effect of IL-37 on aortic sprouting ex vivo. Mouse aortic rings were prepared from wild-type mice aortae and treated with IL-37 with or without antibodies targeting IL-37 for 7 days. Sprouting from explanted aortic rings was significantly increased in the presence of IL-37, whereas the effect was significantly inhibited by IL-37 neutralizing antibodies, confirming the specificity of IL-37 ( Figure 2E ). These results together suggest that IL-37 is a potent proangiogenic factor.
Effects of IL-37 on EC Migration
Migration of ECs toward the angiogenic stimulus is an important early process in angiogenesis. 3 To assess the effect of IL-37 on EC migration, we have determined the effect of IL-37 in a scratch-wound assay. After a scratch wound was created on the monolayer of HUVECs, increasing concentrations of IL-37 (0.1, 1, and 10 ng/mL) were added to the supernatant for 12 hours and cells were monitored 6 and 12 hours after the wound scratch. IL-37 increased wound-induced cell migration at 12 hours post wound formation when compared with control ( Figure 3A and 3B). After wounding, about 374-μm width of the wound surface was covered by migrating HUVECs treated with 1 ng/mL IL-37, whereas 225-μm width of the scratched area was covered by HUVECs treated with vehicle. In the modified Boyden chamber assay, IL-37 also induced an increase in the migrated cells to the lower chamber ( Figure 3C and 3D). The optimal concentration of IL-37 to induce EC migration is ≈0.5 to 1 ng/mL, suggesting the potent effect of IL-37 on EC activation.
IL-37 Activates Survival Signals in ECs
To understand the signaling events induced by IL-37, we examined the major endothelial survival signals, including the extracellular signal-regulated kinase 1/2 (ERK1/2) and the serine-threonine kinase AKT, which are crucial for EC proliferation, survival, and migration. 19, 20 We found that IL-37 stimulated ERK1/2 and AKT activation in time-dependent manner as revealed by phosphorylation of ERK1/2 and AKT, which is consistent with our observation that IL-37 induced EC proliferation and migration. The results suggest that IL-37 promoted angiogenesis probably by activating survival signals relevant to ERK1/2 and AKT signaling ( Figure the molecular mechanism involved in the proangiogenic effect of IL-37, we determined whether IL-37 exerts its proangiogenic function through IL-18Rα or IL-1R8 receptors with neutralizing antibodies. The result showed that antibodies against IL-18Rα or IL-1R8 receptors did not abolish the effect of IL-37 on EC proliferation and migration, suggesting that IL-18Rα and IL-1R8 are not involved in IL-37-induced proangiogenic responses ( Figure VI in the online-only Data Supplement).
IL-37 Enhances Vessel Growth In Vivo in Matrigel Plug Assay
Having demonstrated that IL-37 promotes vascular growth in vitro and ex vivo, we then investigated the angiogenic effect of IL-37 in vivo. We have incorporated IL-37 into Matrigel and then injected the mixture subcutaneously into the middle line of the back in mice. After 7 days of implantation, IL-37 significantly stimulated Matrigel vessel growth in a dose-dependent manner as determined by hemoglobin content and vascular area, with potency comparable with that of basic fibroblast growth factor ( Figure 4A-4C) . To verify the vascular area was blood vessels, sections of Matrigel plugs were immunostained with CD31 and positive area was analyzed ( Figure 4A and 4D) .
The angiogenic response to IL-37 was blocked by antibodies against IL-37 when incorporated in the Matrigel, whereas a preimmune IgG control had no effect on IL-37-induced vessel growth ( Figure VII in the online-only Data Supplement). These results are consistent with the proangiogenic effect of IL-37 on ECs in vitro and on aortic rings ex vivo.
IL-37 Regulates Developmental Angiogenesis in Neonatal Mice
Because our results suggest that IL-37 has a potent effect on angiogenesis in vitro and in vivo, we next investigated whether IL-37 regulates neovascularization under pathological conditions. The retinal vascularization is a widely used model for physiological angiogenesis because the retinal network begins to develop a network from the optic nerve after birth in neonatal mice. 24 To determine the physiological relevance of IL-37 in promoting developmental angiogenesis, neonatal mice were treated with IL-37 (1 ng/g bodyweight) from postnatal day (P)1 to P4. Consistent with the stimulatory role of IL-37 in angiogenesis in vitro and in vivo, IL-37 significantly promoted the spreading of retinal blood vessels toward the retinal periphery at P5 as determined by the vascular area ( Figure 5A and 5B). Immunofluorescence microscopy further showed that the vessel density and tip cell numbers also increased in IL-37-treated mice ( Figure 5C 
IL-37 Promotes Pathological Angiogenesis
In the mouse model of OIR, hypoxia-triggered angiogenic response induces the formation of pathological neovessels, which leave the organized retinal vasculature and grow into the vitreous cavity to form unorganized, small-caliber vessels, termed neovascularization tufts. The highest extension of pathological neovascularization tufts is observed in association with plasma leakage from the neovessels at P17. Thus, neovascularization tufts are considered as the hallmark for characterization of pathological angiogenesis in the OIR model. To assess the effect of IL-37 on pathological angiogenesis, mice were intraperitoneally administrated with recombinant IL-37 at doses of 1 or 5 ng/g bodyweight, respectively, on postnatal day 12 (P12), P14, and P16 during normoxia phase. At P17, IL-37 significantly increased neovascularization tufts in the mouse retinas in a dose-dependent manner ( Figure 6A and 6B), suggesting that IL-37 significantly promotes pathological angiogenesis. The size of avascular region was similar between vehicle and IL-37-treated mice ( Figure 6C ). Administration of antibodies neutralizing IL-37 abolished the proangiogenic effect of IL-37 in neovascularization tufts formation, confirming the specificity of IL-37. IL-37 did not affect retinal vasculature under normoxia conditions, suggesting that IL-37 had no effect on normal vasculature ( Figure IX in the online-only Data Supplement).
However, all the mice treated with IL-37 at the dose of 20 ng/g bodyweight died before P17, most probably because of hypoxia-induced vascular permeability. In addition, as IL-37 is an anti-inflammatory cytokine, to understand the effect of IL-37 on proinflammatory responses during angiogenesis, we determined the expression levels of tumor necrosis factor-α and IL-1β by quantitative polymerase chain reaction in the retinas from neonatal mice and OIR mice. The result showed that IL-1β expression in neonatal retinas was decreased in IL-37-treated mice, and the expression levels of both tumor necrosis factor-α and IL-1β were decreased in OIR retinas from IL-37-treated mice, suggesting that IL-37 inhibited inflammatory cytokine production in retinal angiogenesis ( Figure X in the online-only Data Supplement). These results suggest that IL-37 is a potent proangiogenic cytokine that promotes pathological angiogenesis. Figure 6 . Interleukin (IL)-37 promotes pathological angiogenesis in the mouse model of oxygen-induced retinopathy. A, Mice were administrated with phosphate buffered saline (PBS), 1 or 5 ng/g bodyweight of IL-37 at postnatal day 12 (P12), P14, and P16 during normoxia phase. Mice administrated with 5 ng/g bodyweight of IL-37 were treated with 5 μg/g bodyweight of control IgG or IL-37-neutralizing antibodies at P12, P14, and P16. Disordered neovascular growth (tufts; B) in retina were highlighted in red and quantified. Avascular regions (C) delineated by white boundary line were quantified. Scale bars, 500 μm (lower magnification) and 100 μm (higher magnification); n=8 per group. **P<0.01 and ***P<0.001 Student t test.
Discussion
Our results identified IL-37 as a novel and potent angiogenic cytokine in both pathological and physiological settings. Although IL-37 is emerging as an important anti-inflammatory cytokine, which mainly function intracellularly via interaction with nuclear transcription factor such as Smad3, 10 IL-37 is secreted as an extracellular cytokine under some conditions. For example, the secretion of mature IL-37 from RAW cells with transgenic IL-37 overexpression and PBMCs is induced by ATP, depending on caspase activity. Secretion of IL-37 from dendritic cells can be induced by antibodies against CD94, HLA-I (human leukocyte antigen I), and intercellular adhesion molecule 1. These lines of evidence suggest the possibility that IL-37 functions as an extracellular cytokine. Indeed, as a secreted cytokine, IL-37 is upregulated in the serum of patients with systemic lupus erythematosus, Guillain-Barré syndrome, hepatitis B virus infection, and amyotrophic lateral sclerosis. 14, 15, 16, 17 Here, we observed that IL-37 is expressed by ECs, suggesting angiogenic function of IL-37. Importantly, IL-37 expression and secretion is induced by hypoxia, a well-known proangiogenic conditions that stimulates angiogenesis and vascular alterations. 25 Knockdown of HIF-1α expression inhibited hypoxia-induced upregulation of Il37 mRNA and IL-37 protein levels, indicating that IL-37 expression and secretion are regulated by proangiogenic hypoxic signaling. Interestingly, the principle angiogenic factor VEGF did not have any effect on the expression of IL-37.
To our knowledge, the role of IL-37 on angiogenesis has not been investigated before. On the basis of our results, amounts as low as 10 pg/mL of IL-37 induced EC activation, and low concentration of IL-37 exhibit potent activity in vivo. Aortic rings excised from mice exhibited enhanced vessel sprouting after treatment with IL-37 ex vivo. The increase in vessel sprouting may be because of the effect of IL-37 on EC proliferation and migration as shown by our in vitro studies. The increase in vessel sprouting was specifically inhibited by antibodies against IL-37, suggesting the specificity of the angiogenic activity of IL-37. We have further demonstrated the proangiogenic effect of IL-37 in mouse models in vivo. IL-37 increased vessel growth in the Matrigel plug in a dose-dependent manner. When incorporated at the concentration of 100 ng/mL, the proangiogenic effect of IL-37 was as potent as basic fibroblast growth factor. We further demonstrated that IL-37 significantly promoted neovascularization in developmental and pathophysiological angiogenesis using the mouse model of retinal development and OIR. The mechanism by which IL-37 promotes angiogenesis is under future investigation. Mice carrying transgenic or transient expression of human IL-37 exhibited reduced inflammation in models of hepatitis, colitis, and psoriasis. [26] [27] [28] However, IL-37 transgenic mice have not been reported to exhibit severe vascular abnormalities and embryonic lethality, suggesting that intracellular IL-37 is probably retained intracellularly and was not able to exert its proangiogenic effect in IL-37 transgenic mice.
Survival signals conducted by ERK1/2 and AKT have been recognized to be critical for endothelial activation and viability. 19, 20 We found that IL-37 stimulated ERK1/2 and AKT activation, suggesting that IL-37 promoted angiogenesis probably by activating survival signals relevant to ERK1/2 and AKT signaling. Previous studies have revealed that IL-37 binds to IL-18 receptor as well as IL-1R8. 18, [21] [22] [23] Unexpectedly, IL-18Rα or IL-18 antibodies did not block the effect of IL-37 on EC proliferation and migration, suggesting that IL-18Rα and IL-1R8 are not involved in IL-37-induced proangiogenic responses. Therefore, the identification of the putative receptor that mediates the proangiogenic effect of IL-37 remains unclear and is currently under investigation in our laboratory.
The result that IL-37 suppressed proinflammatory cytokine production in retina angiogenesis raises the question whether IL-37 modulates angiogenic response by modulating proinflammatory reaction. However, many proinflammatory cytokines released during inflammation are potent activators of ECs. 29, 30 For example, it has been suggested that tumor necrosis factor-α directly regulates angiogenesis through increasing ECs survival and vessel maintenance. 31 VEGF is produced in response to proinflammatory cytokines including tumor necrosis factor-α and IL-1. 32 These studies thus argue against the possibility that IL-37 promotes angiogenesis through modulating inflammatory responses. Furthermore, our study showed that IL-37 directly promotes EC proliferation, migration, and tubule formation in vitro, suggesting that IL-37 directly induces angiogenic response through activating ECs.
The dose-dependent effect of IL-37 might be because of several reasons. First, in angiogenic assays, the proangiogenic effects of many angiogenic factors were biphasic. For example, PAI-1 is proangiogenic at physiological concentrations but becomes antiangiogenic at higher concentrations. 33 IL-8 induces chemotaxis and proliferation of ECs at low concentrations, but its activity was reduced at higher concentrations. 34 Another study showed that statins promoted angiogenesis at low concentrations, but inhibited angiogenesis at high concentrations both in vitro and in vivo. 35 Interestingly, angiostatic factors, such as IP-10 and thrombospondin, were reported to suppress angiogenesis at low concentrations but induce EC chemotaxis at high concentrations. [36] [37] [38] The underlying basis of the biphasic functions of angiogenic factors remains to be elucidated. Second, the physiological concentration of IL-37 is typically less than 100 pg/mL in serum. 15 It is thus expected that high doses of IL-37 over the physiological range may cause EC cytotoxicity in experiments.
The identification of IL-37 as a proangiogenic cytokine has important clinical implications. Notably, administration of recombinant IL-37 ameliorates myocardial ischemial injury or hepatic ischemia/reperfusion injury during acute phase in mouse models. 39, 40 According to our results, it is speculated that extracellular IL-37 probably contribute to vascular repair in ischemic injury through promoting angiogenesis in addition to its anti-inflammatory function. Further investigations are in progress to uncover the regulatory role of IL-37 in vascular functions under physiological and pathological settings. Notably, IL-37 is detected in tumor cells of breast carcinoma and infiltrating plasma cells in colon carcinoma, 18 suggesting possible involvement of IL-37 in the pathogenesis of cancer. Thus, further goals are to determine whether blockade of IL-37 is an intriguing strategy for manipulating neovascularization in angiogenesis-related diseases.
